Product Code: SR112023A2544
Abstract
The global enteric disease testing market size reached US$ 4.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.0 Billion by 2028, exhibiting a growth rate (CAGR) of 3.8% during 2022-2028.
Enteric diseases are caused by the entering of microorganisms, such as viruses, bacteria and parasites, in the body through the mouth. These pathogens can be acquired through contaminated food and water or by encountering feces of an animal or infected person. The common symptoms of enteric diseases are abdominal cramps, vomiting, nausea and anorexia that can lead to loss of fluids and essential nutrients from the body. In recent years, advancements in diagnostic technologies have revolutionized enteric disease testing and significantly increased the detection rates in symptomatic individuals.
The improper drainage and sanitation systems, unsafe drinking water and unhygienic living conditions can significantly increase the risk of enteric diseases. This, along with a substantial rise in medical tourism in recent years, represents one of the key factors impelling the market growth. Besides this, the increasing awareness among individuals about the benefits of early diagnosis is acting as another major growth-inducing factor. Apart from this, several international agencies, such as the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), are conducting awareness programs and setting up healthcare camps in different countries to promote the testing of enteric diseases. Moreover, several key players are focusing on the commercialization of novel testing technologies, which is contributing to the market growth. Furthermore, as human coronaviruses cases are associated with enteric diseases, several healthcare institutes are conducting studies to find interrelation between enteric disease and the coronavirus disease (COVID-19).
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global enteric disease testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, technique, disease type and end user.
Breakup by Product Type:
Reagents and Consumables
Equipment
Breakup by Technique:
Molecular Diagnostics
Immunodiagnostics
Breakup by Disease Type:
Bacterial Enteric Disease
C. Difficile
Campylobacteriosis
Cholera
E. Coli
H. Pylori
Salmonellosis
Shigellosis
Viral Enteric Disease
Rotavirus
Norovirus
Others
Parasitic Enteric Disease
Amebiasis
Cryptosporidiosis
Giardiasis
Breakup by End User:
Hospital Diagnostic Laboratories
Independent Diagnostic Laboratories
Academic and Research Institutes
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, BD (Becton, Dickinson and Company), Bio-Rad Laboratories Inc., Biomerica Inc., Biomerieux SA, Cepheid Inc. (Danaher Corporation), Coris BioConcept, DiaSorin, Meridian Bioscience Inc. and Quest Diagnostics.
Key Questions Answered in This Report:
- How has the global enteric disease testing market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global enteric disease testing market?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the technique?
- What is the breakup of the market based on the disease type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global enteric disease testing market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Enteric Disease Testing Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Reagents and Consumables
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Equipment
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Technique
- 7.1 Molecular Diagnostics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Immunodiagnostics
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
8 Market Breakup by Disease Type
- 8.1 Bacterial Enteric Disease
- 8.1.1 Market Trends
- 8.1.2 Major Types
- 8.1.2.1 C. Difficile
- 8.1.2.2 Campylobacteriosis
- 8.1.2.3 Cholera
- 8.1.2.4 E. Coli
- 8.1.2.5 H. Pylori
- 8.1.2.6 Salmonellosis
- 8.1.2.7 Shigellosis
- 8.1.3 Market Forecast
- 8.2 Viral Enteric Disease
- 8.2.1 Market Trends
- 8.2.2 Major Types
- 8.2.2.1 Rotavirus
- 8.2.2.2 Norovirus
- 8.2.2.3 Others
- 8.2.3 Market Forecast
- 8.3 Parasitic Enteric Disease
- 8.3.1 Market Trends
- 8.3.2 Major Types
- 8.3.2.1 Amebiasis
- 8.3.2.2 Cryptosporidiosis
- 8.3.2.3 Giardiasis
- 8.3.3 Market Forecast
9 Market Breakup by End User
- 9.1 Hospital Diagnostic Laboratories
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Independent Diagnostic Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Academic and Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 BD (Becton, Dickinson and Company)
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bio-Rad Laboratories Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Biomerica Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Biomerieux SA
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Cepheid Inc. (Danaher Corporation)
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 SWOT Analysis
- 15.3.7 Coris BioConcept
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 DiaSorin
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Meridian Bioscience Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Quest Diagnostics
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis